Cardiovascular disease remains the largest single cause of mortality in the Western world, despite significant advances in clinical management over the years. Unfortunately, the development of new cardiovascular medicines is stagnating and can in part be attributed to the difficulty of screening for novel therapeutic strategies due to a lack of suitable models. The advent of human induced pluripotent stem cells and the ability to make limitless numbers of cardiomyocytes could revolutionize heart disease modeling and drug discovery. This review summarizes the state of the art in the field, describes the strengths and weaknesses of the technology, and applications where the model system would be most appropriate. 
Introduction
Cardiovascular disease (CVD) account for 1 out of every 3 deaths in the United States [1] . Despite the need, there have been relatively few new drugs over the past decade and the challenges of developing new CVD drugs have caused several major pharmaceutical companies to refocus their efforts away from the field [2] . A potential explanation for the decline in innovative new medicines is a lack of suitable models to screen for novel therapeutic strategies. An exciting new paradigm in cardiovascular drug discovery is the use of human induced pluripotent stem cell (iPSC)-derived cardiomyocytes (iPSC-CMs) and vascular cells to create in vitro models of human physiology. In addition, improvements in high throughput physiological assay technology make it now feasible to optically quantify action potentials [3 ,4 ] , calcium transients [5] [6] [7] , and cell motion [8 ] at scale. Despite the potential impact of these advances, there remains considerable debate as to whether the combination of these two technologies will revolutionize cardiovascular drug discovery. In this review, we discuss the opportunities and challenges of using iPSC-CMs for cardiovascular disease modeling and the implications for drug discovery and safety assessment applications.
Induced pluripotent stem cell-derived cardiomyocytes
iPSC-CM technology has the potential to transform cardiovascular disease modeling, but important caveats limit applicability for some diseases. A major strength of the technology is that iPSC-CMs can be produced in virtually limitless quantities and, in contrast to rodent models, iPSC-CMs enable the study of human genetics and proteins in a native cellular context. This feature is particularly important when studying mechanisms that involve the interaction between multiple proteins, such as the complex signaling cascades of b-adrenergic signaling [9, 10] or the interaction between pore forming a-subunits of ion channels with their ancillary subunits [11] . Additionally, advances in genome editing technologies have enabled the ability to precisely edit or introduce mutations in disease-causing genes to assess the relative contribution of a single mutation on the severity of the disease phenotype [12] . Genome editing is particularly appealing for pharmacogenomic applications as early stage drug candidates can be tested in diverse genetic backgrounds that might confer disease susceptibility.
Despite these advantages, there are clear limitations that hinder the application of iPSC technology in pharmaceutical drug discovery. A major hurdle is that iPSC-CMs are immature relative adult cardiomyocytes. Perhaps most vexing, iPSC-CMs exhibit an immature electrophysiology, morphology, mechanics and metabolism relative to their adult counterparts, despite expressing many of the same proteins and having the same ionic currents, and so more closely resemble fetal rather than adult cardiomyocytes [13] [14] [15] . Specifically, iPSC-CMs have a depolarized diastolic membrane potential compared to adult CMs. Additionally, iPSC-CMs display a circular cell morphology with disorganized sarcomeres and, as a result, the sarcoplasmic reticulum (SR) and transverse tubule (Ttubules) network of iPSC-CMs is underdeveloped. In the absence of these structures, excitation-contraction (EC) coupling does not occur normally and contraction is mediated principally by the influx of extracellular calcium. Fortunately, improving iPSC-CM maturity is an active area of research leading to strategies to improve maturity including long-term culture, culture media alterations [16] [17] [18] [19] , tissue engineered constructs sometimes with physiological stimulation [20] [21] [22] [23] , and matrix patterning [24, 25] . Interestingly, these studies have shown that altering metabolic or morphologic characteristics (e.g. growing individual cells in a 7:1 rectangular pattern) influences electrophysiological and mechanical maturity, suggesting that development of these diverse physiological processes is interrelated.
High-throughput physiological screening of cardiomyocytes
New high throughput methods to quantify the kinetics of excitation and contraction make it possible to conduct physiological screening experiments on a large scale ( Figure 1a ) [26, 27] . Classically, patch clamp electrophysiology is considered the gold standard for measuring action potential (AP) kinetics. High throughput electrophysiology techniques, such as automated planar patch clamp platforms, are routinely used for cell lines [28] , but iPSC-CMs present technical challenges, particularly cell dissociation [29, 30] . MEAs are routinely used to record extracellular field potentials record that report duration of electrical excitation and can distinguish proarrhythmic versus non-proarrhythmic drugs [31] . Additionally, voltage sensitive probes (VSPs) allow for the optical recording of APs from monolayers of iPSC-CMs for both disease modeling and drug testing [3 ,4 ] . VSPs coupled to automated microscopy have advantages over MEA of costeffectiveness and throughput.
Intracellular calcium transients link electrical excitation to contraction, and various methods have been developed to measure the kinetics of both calcium handling and contraction. For calcium handling, small molecule dyes can be used to measure calcium transient kinetics in high throughput [7, 32] .
To quantify contractile kinetics, optical as well as mechanical methods have been developed to study both the kinetics on contraction as well as contraction force. Contractile kinetics, not to be confused with contractile force, are typically measured with video-microscopy enables the quantification of cellular displacement from either bright-field or fluorescent time series images of single cells or monolayers of iPSC-CMs [33] [34] [35] [36] . More complex techniques are required to measure contractile force of individual cells or monolayers including traction force microscopy (TFM) [24] and micro-post deflection assays [37] . Contractile force is the ideal measure, but current methods to quantify force are low throughput and hence cellular displacement is currently used for highthroughput characterization of contractile kinetics.
Applications of iPSC-CMs: suitability for purpose?
iPSC-CMs have been proposed as a new technology that might revolutionize cardiovascular drug discovery, yet their limitations have engendered considerable debate as to the applications for which they can be reliably used. In our opinion, several criteria should be considered when utilizing iPSC-CMs to study CVDs (Figure 1b) . Ideal heart diseases to study with iPSC-CMs (a) have a cardiomyocyte-autonomous etiology, (b) are not predicated on three-dimensional architecture or interactions between multiple cell types and (c) present clinically with a short latency and (if genetic) high penetrance. As a result, congenital heart diseases (CHDs) resulting from mutations in ion channels or contractile proteins are examples of diseases that are readily modeled since clinically relevant phenotypes can be recapitulated in single cardiomyocytes or monolayers of pure cardiomyocytes. Similarly, acquired disease that can be evoked in vitro, such as drug-induced arrhythmia, is possible. On the other hand, anatomical anomalies with unclear cellular etiology, or diseases with long latencies are obviously more challenging.
Heart rhythm disorders
Congenital heart rhythm disorders, such as Long QT Syndrome (LQTS), were the first to be studied using iPSC-CMs [38] [39] [40] [41] [42] . Disease phenotypes of other congenital arrhythmogenic disorders, including catecholaminergic polymorphic ventricular tachycardia (CPVT) [43] [44] [45] and Brugada syndrome [46, 47] , have been demonstrated using iPSC-CM technology. Although standard iPSC-CM differentiation protocols typically generate predominantly ventricular CMs with few atrial and nodal cells, specialized protocols have been developed to yield purely ventricular or atrial iPSC-CMs by defined factors [48] or by purification [49, 50] . As a result, chamber-specific iPSC-CMs can be utilized to study atrial -specific or ventricular-specific pharmacology [51] . Advances in both cellular maturity and multicellular and/or 3D assay systems will likely improve our ability to gain insight into arrhythmia mechanisms involving structural and conduction abnormalities or even morphological remodeling.
Cardiomyopathies
Common familial forms of cardiomyopathy fall into three major classes: hypertrophic cardiomyopathy (HCM) [18, 52, 53] , dilated cardiomyopathy (DCM) [54] [55] [56] [57] , and arrhythmogenic right ventricular cardiomyopathy (ARVC) [58] [59] [60] . Many of the mutations associated with HCM and DCM patients are located in sarcomeric genes, whereas ARVC mutations cluster predominately in desmosomal proteins [61] . Considering the latency and incomplete penetrance of cardiomyopathies within the patient population, it is likely that evoking robust pathological phenotypes will require physiological maturation of iPSC-CMs. Furthermore, additional stressors to mimic environmental factors could exacerbate cardiomyopathy phenotypes in iPSC-CMs. In this regard, several studies have implemented both chemical and mechanical techniques to mature patient-specific iPSC-CMs provoke a pathological phenotype in vitro. Birket et al. [18] developed a triiodothyronine hormone (T3)-based method to promote a contractile HCM phenotype in a MYBPC3-c.2373dupG iPSC-CM line using TFM. Engineered heart tissues (EHTs) have shown promise in modeling DCM as PLN-R14del mutant iPSC-CMs developed dramatically lower twitch force compared to the isogenic counterparts [57] . To model ARVC, Kim et al. [60] treated the iPSC-CMs with a 3-factor cocktail to increase fatty acid oxidation, which is a hallmark of more mature CMs. By activating PPAR-g with small molecules (5-factor), hallmark traits of ARVC (fat deposits, apoptosis) were iPSC models and drug discovery for heart disease Bruyneel et al. 57 Physiological screening of iPSC-CMs -assay readouts and applications. (a) Induced pluripotent stem cells can be derived from patients and differentiated to virtually all cell types of the body, including cardiomyocytes (iPSC-CMs). By utilizing fluorescent dyes excitation-contraction coupling of cardiomyocytes can be measured in high throughput using automated microscopy platforms. Ibutilide is a class III anti-arrhythmic that induces a dose-dependent prolongation of APD and early after depolarizations. Isoproterenol is a non-selective b-adrenoceptor agonist that causes increased beat rate and fastened the decay kinetics of the calcium transients in iPSC-CMs. Mavacamten (MYK-461) is an inhibitor of the cardiac myosin heavy chain ATPase [82] that reduces contractile motion of iPSC-CMs. (b) iPSC-CMs have advantages and limitations that govern their utility of the model for specific applications. Although iPSC-CMs mimic the human context and can be used in high throughput assays, immature physiology and simple cultures are limitations. As a result, disease manifestations need to be CM autonomous and have early onset or can be provoked are most appropriate for study with iPSC-CMs. Examples include channelopathies, cardiomyopathies, and cardiac safety testing.
induced in PKP2 mutant iPSC-CMs. As illustrated by these studies, specific culture conditions and maturationenhancing refinements are key for successful modeling of adult-onset cardiomyopathies.
Cardiac safety
Maybe the most immediate application of iPSC-CMs is their use for safety assessment of preclinical drug candidates. For example, the major reason for drug failure during development or withdrawal after approval is due to an increased risk for Torsades de Pointes (TdP), ventricular arrhythmia or sudden cardiac death. TdP risk is classically predicted by measuring inhibition of the rapidly-activating component of the delayed rectifier potassium current (I Kr ) [62] . However, I Kr inhibition alone is not a robust predictor TdP or lethal arrhythmia. Although the current standard has kept potentially toxic drugs off the market, many safe drugs might have been abandoned [63] [64] [65] [66] [67] . The native, albeit immature, electrophysiology and the ability to conduct high throughput assays make iPSC-CM testing attractive to insert early in the drug development pipeline, perhaps at the point of hit to lead medicinal chemistry refinement [8 , [68] [69] [70] . The suitability of iPSC-CMs for prediction of arrhythmic cardiotoxicity is currently being investigated by the FDA, pharmaceutical companies and academics as part of the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative [71 ,72 ,73] .
Various drugs also induce cardiomyopathy that can lead to major adverse cardiac events and heart failure [74] . iPSCCMs might be an appropriate model to assess myopathic liability. For instance, Burridge et al. [75] investigated the mechanism of doxorubicin toxicity by comparing iPSCCMs derived from patients with differential cardiac susceptibility to doxorubicin. Sharma et al.
[8 ] determined the cardiotoxic propensity of anti-cancer kinase inhibitors in iPSC-CMs, and identified the targeted signaling pathways associated with increased risk. Similarly, Schneider et al. [76] investigated the molecular mechanisms underpinning sorafenib cardiotoxicity, and determined that phosphorylation of phospholamban, a key component of EC coupling, was affected.
Drug discovery and target identification
The drug discovery process typically follows one of two approaches: (1) target-based screening, or (2) phenotypic screening. Phenotypic screening, or screening for modulation of a disease-linked phenotype in a target-agnostic fashion, was historically dominant, but was largely abandoned as a more thorough understanding of biochemistry and physiology sparked a target-driven approach [77, 78 ]. However, phenotypic screens have contributed to about twice as many first-in-class small molecule drugs as solely target-centric approaches [79 ,80] . Target-based approaches do not take into account the role of a target in the disease setting, and underrepresent potentially useful molecular mechanisms of action. Phenotypic screening also has limitations, primarily a more laborious and technically challenging assay development, and for iPSC-CMs, more complex assay modalities such as high content and kinetic imaging. These constraints lead to a lower throughput than target-driven biochemical or cellular assays, thus limiting the chemical space that can be probed. Moreover, identification of targets of hits obtained from phenotypic screens can be quite challenging and constrain hit advancement, including medicinal chemical optimization of the compounds or safety profiling. For these reasons, successful programs often combine both target understanding as well as phenotypic cellular assays to derive drug candidates [78 ] .
Vincent et al. [81] described three criteria for the most predictive phenotypic assays: (1) disease relevance of the assay system, (2) disease relevance of the mechanism that evokes the phenotype, and (3) assay readout proximity to the clinical endpoint. A panel of human patient iPSCCMs is likely to confer disease relevance, provided that the underlying disease mechanisms are sufficiently represented in the simple cultures, and the stimulus is carefully chosen especially for delayed-onset diseases, as discussed above. Using differentiated derivatives, such as iPSCCMs, to recapitulate a clinically relevant readout in a high throughput assay, it should be possible to use chemical and functional genomics (e.g. siRNA and CRISPR screening) to elucidate disease mechanisms and identify novel therapeutic targets. For the first time, it is possible to functionally scan the proteome to identify proteins that can be inhibited to ameliorate disease manifestations in vitro. We expect this approach to reveal a wealth of candidate therapeutic targets that can be validated in animal models and/or clinical genetics. Moreover, funneling the targets into conventional target-centric screens, should generate tool compounds to test the utility of pharmacological inhibition in pre-clinical models.
Conclusions
Phenotypic screening of iPSC-CMs offers the possibility to bring human disease context into the earliest stages of the drug discovery process. We argue that iPSC-CMs are suitable for functional screening in target identification, primary and secondary assays, and cardiac safety. Immaturity, homogeneity, and lack of anatomically appropriate 3D architecture are the main limitations that must be considered in evaluating suitability of iPSC-CMs for particular applications. In the near term, the technology seems most appropriate for modeling diseases with cardiomyocyte autonomous etiology, lack of complex structural presentations, and short latency-consistent with successes in the field in modeling inherited ion channel disorders and myopathies. Maturing the cells to produce more adult-like myocytes is essential and probably linked to the problem of recreating disease-relevant architecture. With more work to address these two issues and reducing them to a screenable setting, the applications of this new technology should expand even further and increase our ability to understand and ultimately treat heart disease.
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